Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO

Primary safety endpoint met; VTP-200 was generally well-tolerated, with no treatment-related grade 3 or higher adverse events or serious AEs . Positive trends in clearance rate for both high-risk HPV...

Related Keywords

United Kingdom , Ukraine , Israel , United States , Gaza , Israel General , American , Barinthus Bio , Barinthus Biotherapeutics , Christopherm Calabrese , Kevin Gardner , Jonothan Blackbourn , Audra Friis , Nadege Pelletier , Exchange Commission , Womens Health Lond , Sam Brown Inc , Nasdaq , American Cancer Society , Bill Enright , Chief Executive Officer , Chief Scientific Officer , Private Securities Litigation Reform Act , Annual Report , Quarterly Reports , Current Reports , Cervical Cancer , Cancer Society , Key Statistics ,